Ataxia Telangiectasia Mutated Proteins
"Ataxia Telangiectasia Mutated Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of PROTEIN-SERINE-THREONINE KINASES which activate critical signaling cascades in double strand breaks, APOPTOSIS, and GENOTOXIC STRESS such as ionizing ultraviolet A light, thereby acting as a DNA damage sensor. These proteins play a role in a wide range of signaling mechanisms in cell cycle control.
Descriptor ID |
D064007
|
MeSH Number(s) |
D08.811.913.696.620.682.700.097 D12.776.157.687.125 D12.776.660.720.125
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ataxia Telangiectasia Mutated Proteins".
Below are MeSH descriptors whose meaning is more specific than "Ataxia Telangiectasia Mutated Proteins".
This graph shows the total number of publications written about "Ataxia Telangiectasia Mutated Proteins" by people in this website by year, and whether "Ataxia Telangiectasia Mutated Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
1997 | 0 | 1 | 1 |
1998 | 0 | 1 | 1 |
1999 | 0 | 3 | 3 |
2000 | 0 | 4 | 4 |
2001 | 0 | 8 | 8 |
2002 | 0 | 1 | 1 |
2003 | 0 | 10 | 10 |
2004 | 0 | 10 | 10 |
2005 | 0 | 9 | 9 |
2006 | 0 | 9 | 9 |
2007 | 0 | 9 | 9 |
2008 | 0 | 10 | 10 |
2009 | 0 | 11 | 11 |
2010 | 0 | 13 | 13 |
2011 | 0 | 14 | 14 |
2012 | 0 | 12 | 12 |
2013 | 3 | 5 | 8 |
2014 | 5 | 8 | 13 |
2015 | 2 | 8 | 10 |
2016 | 5 | 4 | 9 |
2017 | 1 | 6 | 7 |
2018 | 2 | 2 | 4 |
2019 | 3 | 6 | 9 |
2020 | 5 | 5 | 10 |
2021 | 9 | 9 | 18 |
2022 | 0 | 3 | 3 |
2023 | 1 | 6 | 7 |
2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ataxia Telangiectasia Mutated Proteins" by people in Profiles.
-
Targeting ATR in patients with cancer. Nat Rev Clin Oncol. 2024 Apr; 21(4):278-293.
-
Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization. Sci Transl Med. 2024 Feb 14; 16(734):eadj5962.
-
ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clin Cancer Res. 2023 12 01; 29(23):4958-4972.
-
SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma. Clin Cancer Res. 2023 10 02; 29(19):4002-4015.
-
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep; 7:e2300279.
-
Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 07 05; 29(13):2540-2550.
-
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023 Jun; 29(6):1400-1411.
-
Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control. Mol Cell. 2023 03 02; 83(5):660-680.
-
Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity. Int J Biol Sci. 2023; 19(3):981-993.
-
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance. Clin Cancer Res. 2022 10 14; 28(20):4536-4550.